Loading patent…
AssigneePfizer Inc.
InventorsBrendan Murphy, Steven W. Collier, Ernest Quan, Barbara A. Johnson
Estimating the term…
The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.
A dry blend, used for forming azithromycin tablets by direct compression, comprising:
An azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient.
An azithromycin tablet wherein said tablet is produced by:
A pharmaceutical formulation comprises (a) about 80%, by weight, or more, of non-granulated azithromycin;
A method of forming an azithromycin tablet, comprising:
The method of Claim,77 wherein less than about 14% of the total azithromycin particles, by volume as measured by the Malvern method, in the dry blend have a diameter of 44 μm or less.
Dependencies are inferred from the claim text.